Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study

George C Ebers; Anthony T Reder; Anthony Traboulsee; David Li; Dawn Langdon; Douglas S Goodin; Christian Wolf; Karola Beckmann; Andreas Konieczny; Investigators of the 16-Year Long-Term Follow-Up Study

doi:10.1016/j.clinthera.2009.08.003

Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study

George C Ebers, Anthony T Reder, Anthony Traboulsee, David Li, Dawn Langdon, Douglas S Goodin, Christian Wolf, Karola Beckmann, Andreas Konieczny, Investigators of the 16-Year Long-Term Follow-Up Study

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1724-36
Number of pages	13
Journal	Clinical Therapeutics
Volume	31
Issue number	8
DOIs	https://doi.org/10.1016/j.clinthera.2009.08.003
Publication status	Published - Aug 2009

Keywords

Adjuvants, Immunologic
Adult
Dose-Response Relationship, Drug
Double-Blind Method
Female
Follow-Up Studies
Humans
Interferon-beta
Male
Multiple Sclerosis, Relapsing-Remitting
Patient Dropouts
Randomized Controlled Trials as Topic
Retrospective Studies
Validation Studies as Topic
Young Adult

Access to Document

10.1016/j.clinthera.2009.08.003

Cite this

Ebers, G. C., Reder, A. T., Traboulsee, A., Li, D., Langdon, D., Goodin, D. S., Wolf, C., Beckmann, K., Konieczny, A., & Investigators of the 16-Year Long-Term Follow-Up Study (2009). Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clinical Therapeutics, 31(8), 1724-36. https://doi.org/10.1016/j.clinthera.2009.08.003

@article{4589bec3abac475ab0203639e2021ec1,

title = "Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study",

keywords = "Adjuvants, Immunologic, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Humans, Interferon-beta, Male, Multiple Sclerosis, Relapsing-Remitting, Patient Dropouts, Randomized Controlled Trials as Topic, Retrospective Studies, Validation Studies as Topic, Young Adult",

author = "Ebers, {George C} and Reder, {Anthony T} and Anthony Traboulsee and David Li and Dawn Langdon and Goodin, {Douglas S} and Christian Wolf and Karola Beckmann and Andreas Konieczny and {Investigators of the 16-Year Long-Term Follow-Up Study}",

year = "2009",

month = aug,

doi = "10.1016/j.clinthera.2009.08.003",

language = "English",

volume = "31",

pages = "1724--36",

journal = "Clinical Therapeutics",

issn = "0149-2918",

publisher = "Excerpta Medica",

number = "8",

}

Ebers, GC, Reder, AT, Traboulsee, A, Li, D, Langdon, D, Goodin, DS, Wolf, C, Beckmann, K, Konieczny, A & Investigators of the 16-Year Long-Term Follow-Up Study 2009, 'Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study', Clinical Therapeutics, vol. 31, no. 8, pp. 1724-36. https://doi.org/10.1016/j.clinthera.2009.08.003

TY - JOUR

T1 - Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis

T2 - design and lessons from a 16-year observational study

AU - Ebers, George C

AU - Reder, Anthony T

AU - Traboulsee, Anthony

AU - Li, David

AU - Langdon, Dawn

AU - Goodin, Douglas S

AU - Wolf, Christian

AU - Beckmann, Karola

AU - Konieczny, Andreas

AU - Investigators of the 16-Year Long-Term Follow-Up Study

PY - 2009/8

Y1 - 2009/8

KW - Adjuvants, Immunologic

KW - Adult

KW - Dose-Response Relationship, Drug

KW - Double-Blind Method

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Interferon-beta

KW - Male

KW - Multiple Sclerosis, Relapsing-Remitting

KW - Patient Dropouts

KW - Randomized Controlled Trials as Topic

KW - Retrospective Studies

KW - Validation Studies as Topic

KW - Young Adult

U2 - 10.1016/j.clinthera.2009.08.003

DO - 10.1016/j.clinthera.2009.08.003

M3 - Article

C2 - 19808131

SN - 0149-2918

VL - 31

SP - 1724

EP - 1736

JO - Clinical Therapeutics

JF - Clinical Therapeutics

IS - 8

ER -